Placental lactogen Iβ Inhibitors

Placental lactogen Iβ" is a specific variant of the placental lactogen (PL) hormone, which is also known as human chorionic somatomammotropin. PL hormones are produced by the syncytiotrophoblast layer of the placenta during pregnancy and are structurally and functionally related to both human growth hormone (GH) and prolactin (PRL). "Placental lactogen Iβ", in particular, is a member of the growth hormone/prolactin family of hormones, and it exhibits actions that are somewhat intermediate between GH and PRL.The primary role of "Placental lactogen Iβ" is to regulate and support the physiological adaptations occurring in the mother during pregnancy. It helps modulate maternal glucose, protein, and fat metabolism to ensure a continuous supply of nutrients to the growing fetus. By doing so, it plays a crucial role in fetal growth and development. "Placental lactogen Iβ" achieves this by promoting lipolysis, resulting in an increase in maternal blood lipid levels and enhancing insulin resistance to ensure higher glucose levels in the blood, which can be transported to the fetus.

Additionally, "Placental lactogen Iβ" prepares the mammary glands for lactation post-delivery by stimulating the mammary gland development in synergy with other hormones such as estrogen and progesterone. It also stimulates the production of milk proteins during the latter part of pregnancy.The molecular structure of "Placental lactogen Iβ" is critical to its function, as it allows the hormone to bind to both the prolactin and growth hormone receptors in target tissues. This binding elicits various biological responses, including those involved in growth, metabolism, and developmental processes. Dysregulation or abnormal levels of "Placental lactogen Iβ" can have implications for both maternal and fetal health, potentially affecting pregnancy outcomes and fetal development.